New research suggests that people who stop using new GLP-1 drugs like Wegovy and Mounjaro can put back on reduced body mass far faster than those who stop conventional lifestyle programs.
Research printed in a prominent health publication demonstrates that while overweight people often shed a large proportion of their total mass while using the jabs, the weight returns at an estimated rate of 0.8 kg per month upon discontinuation.
"Users purchasing these medications must be aware of the potential of quick weight regain when the therapy is stopped," warns lead investigator Dr. Susan Jebb.
That rate of recovery means a return to original weight within about 18 months.
Comparing Therapies
The study, which examined dozens of trials involving thousands of participants, contrasted the effects of these new drugs with other pills.
Scientists emphasize that people who lose weight through diet and exercise usually experience a less rapid weight regain—around 0.1 kg a month—once they finish.
Explaining the Fast Rebound
Experts believe the mechanism of the injections explains the accelerated rebound.
The injections copy a natural hormone called glucagon-like peptide-1, which controls feelings of fullness.
"Long-term administration of the hormone concentrations far above than the body's typical production could lead to the body to generate a reduced amount of its own natural hormone, and may also diminish responsiveness to its effects," noted Dr. Adam Collins, a nutrition researcher.
"Stopping of this medication leads to appetite is unsuppressed, making binge eating far more likely."
A Lifelong Disease?
The NHS advise the injections for people with obesity-related health risks, alongside prescribed lifestyle changes.
Professionals argue that, due to the significant potential of relapse, the therapy should be considered life-long.
This view is echoed by pharmaceutical companies, who note that the results "emphasize the long-term nature of excess weight," comparing it to managing conditions like diabetes.
Patient Testimonies
Users who have come off the jabs explain a sudden return of appetite.
"It was like a trigger activating and I was suddenly starving," described one woman.
This challenge is compounded if patients have not developed permanent lifestyle or habit modifications during treatment.
Significant Use
Recent estimates suggest that millions of people in the UK have tried weight-loss jabs in the last 12 months, with interest being substantial.
- Use is greater among females compared to men.
- The 40s and 50s demographic shows the greatest usage rates.
- Many obtain the drugs through private prescriptions rather than the NHS.
Ultimately, clinicians emphasize that while GLP-1 drugs are potent tools for weight loss, they are not a magic cure and maintained weight loss hinges on combined lifestyle management.
